Logo

An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13; on behalf of the Predicting MDA in PsA Study Group

  1. Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Italy.
  2. MSD Italy, Rome, Italy.
  3. Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and University of Modena e Reggio Emilia, Italy.
  4. Rheumatology Unit, A.O.U. Policlinico Vittorio Emanuele, Catania, Italy.
  5. Unit of Allergology, Clinical Immunology and Rheumatology, University Campus Bio-Medico, Rome, Italy.
  6. Rheumatology Unit, University of Verona, Italy.
  7. Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.
  8. Rheumatology Unit, Department of Clinical and Molecular Sciences (DISCLIMO), Polytechnic University of Marche, Ancona, Italy.
  9. Department of Medical Sciences, Surgery and Neuroscience, University of Siena, Italy.
  10. Rheumatology Unit, Department of Medicine-DIMED, University of Padova, Italy.
  11. Dipartimento Biomedico di Medicina Interna e Specialistica, Rheumatology Unit, University of Palermo, Italy.
  12. Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Italy.
  13. Rheumatology Unit, Department of Emergence and Transplantation (DETO), University of Bari, Italy. florenzo.iannone@uniba.it

CER11960 Submission on line
Full Papers

Rheumatology Article

 

Abstract

OBJECTIVES:
Recently, research has been focused on the identification of predictors of response to treatment in patients with active psoriatic arthritis (PsA). The objective of this study was to develop a model to predict the clinical response at 6 months in patients with PsA starting the anti-tumour necrosis factor-α golimumab.
METHODS:
This prospective observational study explored a range of factors, including demographic data and baseline characteristics of the disease, measures of disease activity and functional disability, and potential laboratory biomarkers in the prediction of response, defined as the achievement of modified-minimal disease activity (mMDA), to golimumab in PsA patients.
RESULTS:
We studied 151 PsA patients starting golimumab because of their active disease. After 6 months, the rate of drug persistence on golimumab was 80%, and mMDA was achieved in 44.3% of patients. Using univariate and multivariate logistic regression models, lower disease activity in PsA score (DAPSA) at baseline (odds ratio [OR] 0.92; 95% confidence interval [CI] 0.89–0.96, p<0.001) was independent predictor of mMDA at 6 months. High sensitivity C-reactive protein value (OR 1.06; 95% CI 1.00–1.13, p=0.026) at baseline also was a predictive factor of mMDA achievement at 6 months in the laboratory-enhanced prediction model. Golimumab was safe and well tolerated.
CONCLUSIONS:
The identification of factors predictive of response to treatment may help in better understanding the response to golimumab and in identifying PsA patients that are most likely to achieve mMDA following therapy with golimumab.

PMID: 31287400 [PubMed]

Received: 03/12/2018 - Accepted : 09/04/2019 - In Press: 08/07/2019